FDA will add a warning to the label of prostate cancer drugs

10/20/2010 | Wall Street Journal, The

The FDA said the warning label of drugs known as gonadotropin-releasing hormone agonists, used for treating prostate cancer, will mention a potential risk of diabetes and heart disease. The agency previously disclosed that six studies demonstrated a "small increased risk of diabetes and/or cardiovascular disease" among prostate cancer patients using hormone therapy.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ